|FDA Grants Astellas Qualified Infectious Disease Product Designation for ...|
In the event isavuconazole is approved in the United States, the five years QIDP market exclusivity would be in addition to the seven-year exclusivity based on isavuconazole's orphan drug designation for the treatment of zygomycosis that was granted by ...
Wall Street Journal - Thu, 27 Feb 2014 04:00
|Astellas' isavuconazole receives QIDP designation from FDA for zygomycosis ...|
News-Medical.net - Wed, 26 Feb 2014 22:11
|Basilea's isavuconazole designated as QIDP|
Stock Market Wire - Thu, 27 Feb 2014 00:37
|Astellas' mucormycosis drug Isavuconazole gets FDA QIDP designation|
The five years QIDP market exclusivity would be in addition to the seven-year exclusivity based on the drug's orphan drug designation for the treatment of zygomycosis that was granted by the FDA in 2013. In the US, the drug also has FDA fast-track ...
Pharmaceutical Business Review - Sun, 02 Mar 2014 20:52
|Basilea 2013 full-year results: strong operational and financial performance|
In addition to a potentially improved safety profile, isavuconazole, through its spectrum of activity against molds causing zygomycosis (mucormycosis) and its predictable drug exposure, has the potential to overcome a number of limitations of the ...
GlobeNewswire (press release) - Mon, 10 Feb 2014 22:11